NCT04368182 is a Phase 1 clinical trial of Autologous C-TCR055 in Hepatocellular Carcinoma, sponsored by Zhejiang University.

Who is sponsoring NCT04368182?

NCT04368182 is sponsored by Zhejiang University.

What drugs are being tested in NCT04368182?

Interventions in NCT04368182: Autologous C-TCR055.

What condition does NCT04368182 study?

NCT04368182 studies Hepatocellular Carcinoma.

Is NCT04368182 still recruiting?

NCT04368182 is currently status unknown. Last updated 29 April 2020.

Last reviewed 2020-04-29 · How we verify

NCT04368182

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma

Status unknown Phase 1 Last updated 29 April 2020

What this trial tests

Phase 1 trial testing Autologous C-TCR055 in Hepatocellular Carcinoma in 3 participants. Status unknown.

Timeline

13 April 2020

Primary endpoint
31 August 2020

30 November 2021

Quick facts

Lead sponsor	Zhejiang University
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	13 April 2020
Primary completion	31 August 2020
Estimated completion	30 November 2021
Sites	1 location across China

Drugs / interventions tested

Autologous C-TCR055 — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Zhejiang University

Who can join

Adults 18 to 70, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study that aimed to assess the safety and anti-tumor activity of C-TCR055 injection in unresectable HCC patients

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
Liu Z, Liu X, Liang J, Liu Y, et al · · 2021 · cited 109× · PMID 34675942 · DOI 10.3389/fimmu.2021.765101
Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.
Dai X, Guo Y, Hu Y, Bao X, et al · · 2021 · cited 58× · PMID 33537099 · DOI 10.7150/thno.54648
Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials.
Rochigneux P, Chanez B, De Rauglaudre B, Mitry E, et al · · 2021 · cited 53× · PMID 33450845 · DOI 10.3390/cancers13020271
Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making.
Dhanasekaran R, Suzuki H, Lemaitre L, Kubota N, et al · · 2025 · cited 42× · PMID 37300379 · DOI 10.1097/hep.0000000000000513
Evolution of CD8<sup>+</sup> T Cell Receptor (TCR) Engineered Therapies for the Treatment of Cancer.
Sun Y, Li F, Sonnemann H, Jackson KR, et al · · 2021 · cited 34× · PMID 34572028 · DOI 10.3390/cells10092379
Novel Cellular Therapies for Hepatocellular Carcinoma.
Roddy H, Meyer T, Roddie C. · · 2022 · cited 24× · PMID 35158772 · DOI 10.3390/cancers14030504
Cellular based immunotherapy for primary liver cancer.
Zheng Y, Li Y, Feng J, Li J, et al · · 2021 · cited 24× · PMID 34372912 · DOI 10.1186/s13046-021-02030-5
Immunotherapy for hepatocellular carcinoma.
Wang X, Lu J. · · 2024 · cited 22× · PMID 38855876 · DOI 10.1097/cm9.0000000000003060

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Zhejiang University trials

Trials by the same sponsor.

NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04368182 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
Last refreshed: 29 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04368182.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing